• UCLA Health
  • myUCLAhealth
  • School of Medicine
Neurology

UCLA Neurology

Neurology
  • About Us
    • Chair's Welcome
    • Contact Us
    • Department of Neurology Strategic Plan
    • Neurology Chair's Reports
    • Brains of Neurology
    • Publications, News and Events
    • Giving
    • Employment Opportunities
    • Calendar
  • Clinical Programs
    • Mary S. Easton Center for Alzheimer's Disease Research at UCLA
    • Behavioral Neurology
    • Epilepsy
    • General Neurology
    • UCLA Goldberg Migraine Program
    • Movement Disorders
    • Multiple Sclerosis
    • The Marilyn Hilton MS Achievement Center at UCLA
    • Neurocritical Care
    • Neurogenetics
    • Neuromuscular
    • Neurophysiology
    • Neuro-Infectious Diseases
    • Neuro-Oncology
    • Neuro-Otology
    • Neuro-Rehabilitation
    • Sleep Disorders
    • Stroke
    • Mary S. Easton Center for Alzheimer's Disease Research at UCLA
    • Behavioral Neurology
    • Epilepsy
    • General Neurology
    • UCLA Goldberg Migraine Program
    • Movement Disorders
    • Multiple Sclerosis
    • The Marilyn Hilton MS Achievement Center at UCLA
    • Neurocritical Care
    • Neurogenetics
    • Neuro-Infectious Diseases
    • Neuromuscular
    • Neuro-Oncology
    • Neuro-Otology
    • Neurophysiology
    • Neuro-Rehabilitation
    • Sleep Disorders
    • Stroke
  • For Patients
    • Contact Us
    • Find a Doctor
    • Our Locations
    • Parking Guide for Westwood Clinic
    • Clinical Programs
    • Be part of Neurogenomics research
    • Patient Education
    • Referrals / Consults / Medical Records
  • Research Innovation
    • Mary S. Easton Center for Alzheimer's Disease Research at UCLA
    • Brain Mapping
    • Epilepsy
    • UCLA Goldberg Migraine Program
    • Health Services
    • Movement Disorders
    • Multiple Sclerosis
    • Neurogenetics
    • Clinical Neurogenomics Research Center (CNRC)
    • Neuro-Infectious Diseases
    • Neuromuscular
    • Neuro-Oncology
    • Neuro-Otology
    • Neuroscience Discovery
    • Neurophysiology
    • Neuro-Rehabilitation
    • Sleep Disorders
    • Stroke
  • Clinical Trials
  • Education
    • Residency
    • Fellowships
    • Research
    • Medical Students
    • Unique Programs
    • Education Leadership Team
    • Practice Locations
    • Contact Us
  • For Healthcare Professionals
    • Calendar
    • Referrals / Consults / Medical Records
    • Employment Opportunities
    • Find a Physician
    • News & Events
  • Faculty & Staff
    • Westwood Faculty
    • Faculty at Affiliated and Partner Sites
    • Community Neurologists
    • Staff Providers
    • Fellows
    • Residents
    • Researchers
    • Voluntary Faculty
    • Emeritus Faculty
    • Research Trainees
    • Admin Staff
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Neurology

About Us

About Us

About Us

  • Chair's Welcome
  • Contact Us
  • Department of Neurology Strategic Plan
  • Neurology Chair's Reports
  • Brains of Neurology
  • Publications, News and Events
  • Giving
  • Employment Opportunities
  • Calendar
  • Chair's Welcome
  • Contact Us
  • Department of Neurology Strategic Plan
  • Neurology Chair's Reports
  • Brains of Neurology
  • Publications, News and Events
  • Giving
  • Employment Opportunities
  • Calendar
  1. Home
  2. About Us
  3. Publications, News and Events

Publications, News and Events

Share this
Image
https://www Photo

Dr. Claude Wasterlain: Early polytherapy for benzodiazepine-refractory status epilepticus

November 18, 2019

(Abstract from PubMed)

"The transition from single seizures to status epilepticus (SE) is associated with malaptive trafficking of synaptic gamma-aminobutyric acid (GABAA) and glutamate receptors. The receptor trafficking hypothesis proposes that these changes are key events in the development of pharmacoresistance to antiepileptic drugs (AEDs) during SE, and that blocking their expression will help control drug-refractory SE (RSE). We tested this hypothesis in a model of SE induced by very high-dose lithium and pilocarpine (RSE), and in a model of SE induced by sc soman. Both models are refractory to benzodiazepines when treated 40?min after seizure onset. Our treatments aimed to correct the loss of inhibition because of SE-associated internalization of synaptic GABAA receptors (GABAAR), using an allosteric GABAAR modulator, sometimes supplemented by an AED acting at a nonbenzodiazepine site. At the same time, we reduced excitation because of increased synaptic localization of NMDA and AMPA (?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and N-methyl-D-aspartate) receptors (NMDAR, AMPAR (?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, N-methyl-D-aspartate receptors)) with an NMDAR channel blocker, since AMPAR changes are NMDAR-dependent. Treatment of RSE with combinations of the GABAAR allosteric modulators midazolam or diazepam and the NMDAR antagonists dizocilpine or ketamine terminated RSE unresponsive to high-dose monotherapy. It also reduced RSE-associated neuronal injury, spatial memory deficits, and the occurrence of spontaneous recurrent seizures (SRS), tested several weeks after SE. Treatment of soman-induced SE also reduced seizures, behavioral deficits, and epileptogenesis. Addition of an AED further improved seizure outcome in both models. Three-dimensional isobolograms demonstrated positive cooperativity between midazolam, ketamine, and valproate, without any interaction between the toxicity of these drugs, so that the therapeutic index was increased by combination therapy. The midazolam-ketamine-valproate combination based on the receptor trafficking hypothesis was far more effective in stopping RSE than the midazolam-fosphenytoin-valproate combination inspired from clinical guidelines for the treatment of SE. Furthermore, sequential administration of midazolam, ketamine, and valproate was far less effective than simultaneous treatment with the same drugs at the same dose. These data suggest that treatment of RSE should be based at least in part on its pathophysiology. The search for a better treatment should focus on the cause of pharmacoresistance, which is loss of synaptic GABAAR and gain of synaptic glutamate receptors. Both need to be treated. Monotherapy addresses only half the problem. Improved pharmacokinetics will not help pharmacoresistance because of loss of receptors. Waiting for one drug to fail before giving the second drugs gives pharmacoresistance time to develop. Future clinical trials should consider treating both the failure of inhibition and the runaway excitation which characterize RSE, and should include an early polytherapy arm."

Read more in Epilepsy & Behavior.

Back to Search
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest

Sign in to myUCLAhealth